This suggests that the agency is using 704(a)(4) requests as a strategic tool for international facilities, likely for the purpose of utilizing resources efficiently
For instance, Novo Nordisks once-daily GLP-1 agonist Saxenda is approved as a weight loss drug in people with a body mass index (BMI) greater than 30 kg/m 2 (considered obesity), or greater than 27 kg/m 2 (considered overweight) with at least one additional weight-related condition (such as type 2 diabetes, high cholesterol, high blood pressure, etc.)
Its something youll want to discuss with your doctor
GLP-1 (7-36) has a short half life of less than 2 minutes, and like GIP, is rapidly degraded by the enzyme dipeptidyl peptidase IV (DPP-4), which is widely expressed in a number of sites, including the endothelial cells of small gut arterioles
Others feel off for a few days after each injection, especially in week one or two